Todays Report: Today, Nabriva Therapeutics AG (NBRV) Lowered by The Zacks Investment Research

Today, Nabriva Therapeutics AG (NBRV) Lowered by The Zacks Investment Research

Zacks Investment Research lowered shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

Other analysts have also issued research reports about the company. HC Wainwright initiated coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a buy rating and a $16.00 price objective on the stock. Leerink Swann reaffirmed an outperform rating and set a $14.00 price objective on shares of Nabriva Therapeutics AG in a research note on Thursday, October 27th. Finally, Wedbush reiterated an outperform rating and set a $17.00 target price on shares of Nabriva Therapeutics AG in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $13.15.

Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.22 on Tuesday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $10.69. The stock’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00.

Institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP purchased a new position in Nabriva Therapeutics AG during the third quarter worth approximately $2,468,000. Opaleye Management Inc. increased its position in Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares during the period. Finally, Jackson Park Capital LLC purchased a new position in Nabriva Therapeutics AG during the second quarter worth approximately $195,000. Institutional investors own 63.09% of the company’s stock.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

Related posts

Leave a Comment